Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 13(39): 5180-7, 2007 Oct 21.
Article in English | MEDLINE | ID: mdl-17876888

ABSTRACT

AIM: To elucidate risk factors contributing to the development of hepatocellular carcinoma (HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment and to examine whether HCV-RNA still remained in the liver of SVR patients who developed HCC. METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in this study. We retrospectively reviewed clinical, viral and histological features of the patients, and examined whether the development of HCC depends on several clinical variables using Kaplan-Meier Method. RT-PCR was used to seek HCV-RNA in 3 out of 7 patients in whom liver tissue was available for molecular analysis. RESULTS: Among the enrolled 266 patients with SVR, HCC developed in 7 patients (7/266; 2.6%). We failed to detect HCV-RNA both in cancer and non-cancerous liver tissue in all three patients. The cumulative incidence for HCC was significantly different depending on hepatic fibrosis (F3-4) (P = 0.0028), hepatic steatosis (Grade 2-3) (P = 0.0002) and age (> or = 55) (P = 0.021) at the pre-interferon treatment. CONCLUSION: The current study demonstrated that age, hepatic fibrosis, and hepatic steatosis at pre-interferon treatment might be risk factors for developing HCC after SVR.


Subject(s)
Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/etiology , Fatty Liver/complications , Hepacivirus/drug effects , Hepatitis C/drug therapy , Liver Neoplasms/etiology , Aged , Carcinoma, Hepatocellular/pathology , Fatty Liver/pathology , Female , Follow-Up Studies , Hepacivirus/pathogenicity , Hepatitis C/pathology , Humans , Interferons/therapeutic use , Kaplan-Meier Estimate , Liver/pathology , Liver/virology , Liver Neoplasms/pathology , Male , Middle Aged , RNA, Viral/blood , Retrospective Studies , Ribavirin/therapeutic use , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...